On 10/7/2013, Mikaela Knapp was diagnosed with cancer. Over the course of testing in the subsequent weeks, her cancer was identified as metastatic translocation renal cell carcinoma (RCC).
Mikaela immediately started treatment at University of California, San Francisco, completing a round of Sutent, Axitinib, and Afinitor, gamma knife brain radiation, spinal radiation, whole brain radiation, and several rounds of Torisel, .
In March, after exhausting all of the FDA-approved options our oncologists felt could help Mikaela, we decided to push for compassionate use access to the anti-PD-1/L1 immunotherapies of Bristol-Myers Squibb, Genentech, and Merck which are currently in clinical trials. For more info, see our petition.